March 28th 2025
Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.
Novartis Vaccines begins shipment of seasonal influenza vaccine
August 17th 2010Novartis Vaccines has started shipping the FDA-approved seasonal influenza vaccine Fluvirin to U.S. customers ahead of the 2010&endash;2011 season, allowing healthcare practitioners to initiate protection of their patients well in advance.
FDA issues warning on stolen Advair Diskus inhalers
August 17th 2010Certain lots of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers that were stolen from a GlaxoSmithKline (GSK) distribution warehouse near Richmond, Va., in August 2009 have recently been found in some pharmacies, according to FDA.
FDA approves 3-in-1 combination drug for high blood pressure
August 17th 2010FDA has approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once daily for the treatment of hypertension in patients who are not adequately controlled on any 2 of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics, according to Daiichi Sankyo Inc.
Newer AEDs linked to self-harm, suicidal behavior
August 17th 2010Patients taking newer antiepileptic drugs (AEDs) that are associated with a high risk of depression may have an elevated risk of self-harm or suicidal behavior, but other groups of AEDs do not appear to carry the same risk, according to research published in the July 27 issue of Neurology and reported in HealthDay News.
OAD agents effective in reducing hemoglobin levels up to 1.5%
August 17th 2010Oral antidiabetic (OAD) agents generally result in a maximum 1.5% drop in hemoglobin (Hb) A1C levels, with sulfonylureas and thiazolidinediones having a slightly more beneficial effect than other classes of oral agents, according to research published in the August issue of Diabetes Care and reported by HealthDay News.
Naltrexone, bupropion combination helps individuals lose excess weight
August 17th 2010Investigational combination treatment with sustained-release (SR) naltrexone and bupropion (Contrave, Orexigen Therapeutics) combined with lifestyle modification, appears effective in helping people lose 5% or more of their excess body weight, according to research published online July 30 in The Lancet and reported by HealthDay News.
Generic substitution: An opportunity to educate consumers
August 15th 2010In a recent survey by Medco Health Solutions Inc., only 66% of 1,092 patients with insurance surveyed "agreed that a generic drug is the same as the brand-name medication - many patients are still not comfortable using a generic and others still consider brand-name drugs to be superior."
Keeping pharmacy staff: Best practices
August 15th 2010With many pharmacists approaching retirement, positions are opening up. For professionals tasked with greater responsibility and longer working hours, greener pastures have an undeniable appeal. In this business climate, how can employers hold onto their pharmacy professionals?
Protect skin from sun damage: Educate patients
August 15th 2010Pharmacists are in a good position to tell patients that sand, water, snow, and clouds reflect and intensify the sun's rays, causing unsuspected sun damage, even in shade, and that protecting skin from sun damage should be incorporated into a daily routine.
Prescriptions for pharmacy survival may be a bitter pill
August 15th 2010Most of us probably didn't pay a lot of attention to business majors when we were in college. Unfortunately, the business majors have far more influence over the practice of pharmacy today than pharmacists do, and it's going to be up to them to find a way out of the pickle our profession finds itself in.
CER: Separating fact from fiction
August 15th 2010The 2,400-page healthcare reform bill included language establishing the Patient Centered Outcomes Research Institute, a group grounded in the tenets of comparative effectiveness research. Its mission is significant, but whether it has the power to effect change remains to be seen.
PPACA creates approval pathway for follow-on biologics
August 15th 2010Although the Patient Protection and Affordable Care Act (PPACA) creates an abbreviated approval pathway for biological products that are demonstrated to be ?highly similar? (biosimilar) to or ?interchangeable? with an FDA-approved biological product, only time will tell how long it will take for these biosimilars to reach the marketplace.
Fluzone High-Dose vaccine covered under Medicare Part B
July 20th 2010Written confirmation is now available from the Centers for Medicare and Medicaid Services indicating that Fluzone High-Dose (Sanofi Pasteur) influenza virus vaccine for patients 65 years or older is a benefit covered by Medicare Part B and will be reimbursed for the upcoming 2010?11 influenza season.
CMS favors continued local pharmacy distribution of diabetes-testing supplies to seniors
July 20th 2010The Centers for Medicare & Medicaid Services (CMS) issued a proposed regulation on June 25 that would exempt community pharmacies from the upcoming bidding process for Medicare Part B diabetes-testing supplies, along with instructions that exempt most independent community pharmacies from accreditation requirements.